Moderna Inc (NASDAQ: MRNA) on Tuesday, soared 5.68% from the previous trading day, before settling in for the closing price of $30.97. Within the past 52 weeks, MRNA’s price has moved between $23.15 and $125.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -42.94% annually for the last half of the decade. The company achieved an average annual earnings per share of -9.91%. With a float of $342.49 million, this company’s outstanding shares have now reached $387.00 million.
In an organization with 5800 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 52.55%, operating margin of -118.04%, and the pretax margin is -107.82%.
Moderna Inc (MRNA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Moderna Inc is 11.44%, while institutional ownership is 72.36%. The most recent insider transaction that took place on Jun 11 ’25, was worth 8,736. In this transaction Director of this company sold 312 shares at a rate of $28.00, taking the stock ownership to the 580 shares. Before that another transaction happened on Jun 11 ’25, when Company’s Director proposed sale 312 for $28.00, making the entire transaction worth $8,736.
Moderna Inc (MRNA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -9.91% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.17% during the next five years compared to -42.94% drop over the previous five years of trading.
Moderna Inc (NASDAQ: MRNA) Trading Performance Indicators
Moderna Inc (MRNA) is currently performing well based on its current performance indicators. A quick ratio of 4.14 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.72, a number that is poised to hit -2.98 in the next quarter and is forecasted to reach -7.60 in one year’s time.
Technical Analysis of Moderna Inc (MRNA)
Let’s dig in a bit further. During the last 5-days, its volume was 6.77 million. That was inferior than the volume of 11.06 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 27.77%.
During the past 100 days, Moderna Inc’s (MRNA) raw stochastic average was set at 63.99%, which indicates a significant decrease from 71.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.44 in the past 14 days, which was lower than the 1.64 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.03, while its 200-day Moving Average is $36.17. However, in the short run, Moderna Inc’s stock first resistance to watch stands at $33.39. Second resistance stands at $34.04. The third major resistance level sits at $35.25. If the price goes on to break the first support level at $31.53, it is likely to go to the next support level at $30.32. The third support level lies at $29.67 if the price breaches the second support level.
Moderna Inc (NASDAQ: MRNA) Key Stats
Market capitalization of the company is 12.66 billion based on 386,742K outstanding shares. Right now, sales total 3,236 M and income totals -3,561 M. The company made 108,000 K in profit during its latest quarter, and -971,000 K in sales during its previous quarter.
